申请人:British Bio-Technology Limited
公开号:US05180723A1
公开(公告)日:1993-01-19
Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --; A.sup.2 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.2 --; provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the other variables are as defined in the specification and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.
通式I的化合物;其中:A.sup.1为.dbd.N--,.dbd.CH--或.dbd.CR.sup.1--; A.sup.2为.dbd.N--,.dbd.CH--或.dbd.CR.sup.2--; 前提是,当A.sup.1和A.sup.2中的一个是氮原子时,另一个不是氮原子;其中其他变量如规范中定义的那样,它们的药用和兽医学可接受的酸盐和水合物是血小板活化因子(PAF)的拮抗剂,因此在治疗或改善由PAF介导的各种疾病或紊乱方面是有用的。